CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer

Area of Science:

• Oncology
• Cancer Biology
• Immunology

Background:

• Poly (ADP-ribose) Polymerase inhibitors (PARPi) are effective against ovarian cancer (OV) with BRCA1/2 mutations.
• Drug resistance to PARPi limits their clinical application, necessitating novel therapeutic strategies.
• PARPi sensitivity is linked to cell cycle dysfunction.

Purpose of the Study:

• To identify novel agents that synergize with PARPi to overcome drug resistance in ovarian cancer.
• To investigate the mechanistic basis of synergistic effects between a cell cycle inhibitor and Olaparib.
• To evaluate the therapeutic potential of combining CDC7 inhibitors with PARPi in preclinical models.

Main Methods:

• High-throughput drug screening of a cell cycle kinase inhibitor library.
• In vitro and in vivo studies combining Olaparib with XL413, a CDC7 inhibitor.
• Assessment of DNA damage, replication stress, and immune response (cGAS/STING pathway).
• Evaluation of anti-tumor efficacy in murine syngeneic tumor models.

Main Results:

• XL413, a CDC7 inhibitor, was identified as a synergistic agent with Olaparib.
• Combined treatment induced significant DNA damage and replication stress, enhancing Olaparib sensitivity.
• The combination therapy activated the cGAS/STING signaling pathway, triggering a type-I interferon response.
• Synergistic treatment led to enhanced anti-tumor immunity and tumor regression in preclinical models.

Conclusions:

• Combining CDC7 inhibitors with PARPi represents a promising therapeutic strategy for advanced ovarian cancer.
• This approach can overcome PARPi resistance and enhance anti-tumor immunity.
• The findings offer a potential new treatment option for patients with limited response to PARPi.